|Videos|October 12, 2022
Determining Treatment Duration for Transplant-Eligible NDMM
Author(s)Ajay K. Nooka, MD, Matthew James Pianko, MD
Dr Matthew James Pianko details how he determines treatment duration and discontinuation for transplant-eligible multiple myeloma.
Advertisement
Advertisement
Related to this article
Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.
Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.
There is a gap in prospective data for radiation use in multiple myeloma, according to Alexandra Dreyfuss, MD, MS.
Ralph V. Boccia, MD, FACP, compared MRD data with Tec-Dara and Tal-Dara and explained how sustained MRD negativity is reshaping myeloma care.
Alexandra Dreyfuss, MD, MS, weighs bridging vs consolidative radiotherapy strategies around CAR T-cell infusion in myeloma.
Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
Ralph V. Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration multiple myeloma care.
Ralph V. Boccia, MD, FACP, discussed how time since CAR T-cell therapy and toxicity profiles guide bispecific selection in relapsed multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Meaning-Centered Therapy, Psychiatry Referrals, and Humanistic Cancer Care
2
How Psycho-Oncology Addresses Existential Distress, Body Image, and Intimacy
3
How to Work With a Patient Who Declines Cancer Treatment
4
Targeting Cyclin E1, KRAS, and DNA Repair Beyond PARP in Ovarian Cancer
5